Actionable news
All posts from Actionable news
Actionable news in OVAS: Ovascience Inc.,

Ovascience Reports Third Quarter 2015 Financial Results

The following excerpt is from the company's SEC filing.


(NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported third quarter 2015 financial results and highlighted recent accomplishments.

The recent publication of the AUGMENT patient experiences highlighted the clinical benefit of the treatment in patients with poor fertility prognoses, said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. We continue to adapt our commercial operations to reflect rapid changes in the fertility market. Our hi gh-quality, scalable manufacturing and technical operations give us confidence in our ability to expand into new territories, such as Europe and Japan, while building a strong foundation for introducing our other treatments. We remain on track to introduce our OvaPrime treatment this year through a preceptorship program in at least one international region to evaluate its potential in women with too few or no eggs. We also continue to expect to communicate by year end a development pathway for OvaTure, our next-generation, hormone-free approach to IVF.

Third Quarter and Recent Highlights

Treatment Peer-Reviewed Publication Showed Statistically Significant Improvements in Embryo Selection and Transfer Compared to Standard IVF

First published analysis comparing the AUGMENT treatment to standard IVF using an egg allocation method demonstrated statistically significant higher rates of embryo selection and transfer with the AUGMENT treatment based on standard embryo quality measures, including preimplantation genetic diagnosis/screening. Improved pregnancy rates with the AUGMENT treatment were also reported in the publication. These positive results were published in the

Journal of Fertilization: In Vitro IVF-Worldwide

and presented at a recent scientific symposium. Additionally, physicians offering the AUGMENT treatment reported 22 babies born with the treatment to date. The AUGMENT treatment is not available in the United States.

Hosted Scientific Symposium for Healthcare Providers on Advances in Egg Health

Participated in the American Society for Reproductive Medicine (ASRM) Annual Meeting and held a scientific symposium focused on educating clinicians on the importance of egg health and new advances in fertility. The event featured experts on the role of mitochondria for healthy embryogenesis and the potential of egg precursor (EggPC

) cells for developing novel fertility treatments. In addition, a summary of the first published AUGMENT treatment patient experience was presented.

On Track to Introduce the OvaPrime

Treatment Through Preceptorship Program

Company expects to meet goal of introducing the OvaPrime treatment to patients through a preceptorship program in at least one international region outside the United States by year end. This initial preceptorship program is a non-commercial training period in which physicians gain clinical experience using the OvaPrime treatment to replenish the ovarian reserve in women who make too few or no eggs. The Company expects physicians will share their initial patient experiences as clinically meaningful insights become available.

Advanced Development Plans for the OvaTure

Finalizing plans for the further development of the OvaTure treatment, a next-generation fertility...